Mezzion Pharma Co.,Ltd. (KOSDAQ:A140410) announced a private placement of first unregistered coupon unguaranteed unsecured private convertible bonds for gross proceeds of KRW 42,000,000,000 on July 14, 2015. Kiwoom Investment Co., Ltd.; Synergy Partners Co., Ltd.; Hanyang Securities Co. Ltd., Investment Arm; NH Investment & Securities Co., Ltd., Investment Arm; Anda Cruise PEF 1 through NH Investment & Securities Co., Ltd., Investment Arm; Future-Creation Neoplux Venture Capital Fund, a fund managed by Neoplux Co, Ltd.; KTB Asset Management Co.; Korea Securities Finance Corporation, Investment Arm; and Genexine, Inc. each will subscribe bonds for KRW 12,000,000,000; KRW 6,000,000,000; KRW 4,000,000,000; KRW 3,000,000,000; KRW 5,000,000,000; KRW 5,000,000,000; KRW 5,000,000,000; and KRW 2,000,000,000 respectively.

The bonds will not carry any interest and will have a yield to maturity of 1%. The bonds will mature on July 16, 2020. The bonds will be convertible into common shares of the company at a fixed conversion price of KRW 43,591 per share at 100% conversion rate from July 16, 2016 to July 16, 2020.

The bonds will be redeemable in lump sum on its maturity. The board of directors approved the transaction. The securities will be issued at its par value.

The payment and subscription date is July 16, 2015.